相关临床试验
14
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
21.4%
已完成
5
35.7%
招募中
6
42.9%
暂无批准数据
- The Global Health Innovative Technology Fund announced a $460,000 investment to develop a prototype mpox detection test capable of distinguishing between viral clades using the Iso-PAS genetic testing method. - The project involves NIPRO Corporation, TBA Co. Ltd, Japan Institute for Health Security, PATH, and Institut National de Recherche Biomédicale to create rapid diagnostics for resource-limited settings. - Over 170,000 mpox cases were confirmed in 141 countries between January 2022 and October 2025, with children under 5 years showing case fatality ratios of 7-9% in the Democratic Republic of Congo. - Current diagnostic systems for identifying mpox clades remain insufficient, creating urgent need for simple, rapid tests to prevent further infection spread in sub-Saharan Africa.
- Samsung Bioepis has entered into a strategic partnership with NIPRO Corporation for the development and commercialization of multiple biosimilar candidates in Japan, including SB17, a ustekinumab biosimilar. - Under the agreement, Samsung Bioepis will handle development, manufacturing and supply while NIPRO will be responsible for commercialization activities in the Japanese market. - The partnership aims to expand treatment access and bring cost savings to Japan's healthcare system across multiple therapeutic areas including immunology, oncology, and endocrinology.
